A Phase 4 interventional study of Canagliflozin + Metformin hydrochloride (Fixed Dose Combination) in Diabetes Mellitus, sponsored by Johnson & Johnson Private Limited. Completed at 10 sites in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Johnson & Johnson Private Limited (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing canagliflozin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. Canagliflozin · Diabetes Mellitus.
Among the 12 studies testing canagliflozin in Diabetes Mellitus, this one is the 4th largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 4, and was the 9th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →None of the 12 studies testing canagliflozin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →
Canagliflozin: first FDA approval 2013 (INVOKANA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 5 · Phase 4 3
First in 2008; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 276 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 84 across the 12 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Private Limited, one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Private Limited is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
28 studies in Diabetes Mellitus by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 26 finished, 7 (27%) have results posted.
Among the 28 studies in Diabetes Mellitus by Johnson & Johnson, this one is the 6th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 4, and was the 28th registered.
Johnson & Johnson’s Diabetes Mellitus studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing canagliflozin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 28 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess safety of canagliflozin + metformin hydrochloride immediate Release (IR) fixed-dose combination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration.
Drug: Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)
Drug pages: CanagliflozinStudies of CanagliflozinCanagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration. The study Treatment duration will be of 24 weeks.
Also known as: JNJ-28431754
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product. TEAEs were defined as events that started on or after the study medication start date and time.
Time frame: Baseline (Day 1) up to 24 weeks
Percentage of Participants With Unexpected Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An adverse event was considered unexpected if the nature or severity was not consistent with the applicable product reference safety information.
Time frame: Baseline (Day 1) up to 24 weeks
Percentage of Participants With Adverse Drug Reactions (ADRs)
ADRs were defined as the treatment related TEAEs. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs were defined as events that started on or after the study medication start date and time.
Time frame: Baseline (Day 1) up to 24 weeks
Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24
Percent change from baseline in HbA1c at Weeks 12 and 24 was reported.
Time frame: Baseline, Weeks 12 and 24
| Milestone | Canagliflozin + Metformin Hydrochloride FDC |
|---|---|
| Started | 276 |
| Treated | 274 |
| Completed | 265 |
| Not completed | 11 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Adverse event | 5 |
| Withdrew: Non-compliance with study drug | 1 |
| Withdrew: Other | 1 |
| Withdrew: Started but not treated | 2 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product. TEAEs were defined as events that started on or after the study medication start date and time.
| Percentage of participants | Canagliflozin + Metformin Hydrochloride FDC |
|---|---|
| TEAEs | 41.6 |
| TESAEs | 1.1 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An adverse event was considered unexpected if the nature or severity was not consistent with the applicable product reference safety information.
| Percentage of participants | Canagliflozin + Metformin Hydrochloride FDC |
|---|---|
| Percentage of Participants With Unexpected Adverse Events (AEs) | 0 |
Percent change from baseline in HbA1c at Weeks 12 and 24 was reported.
| Percent change | Canagliflozin + Metformin Hydrochloride FDC |
|---|---|
| Percent change at Week 12 | -0.918 ± 1.1348 |
| Percent change at Week 24 | -0.926 ± 1.3054 |
ADRs were defined as the treatment related TEAEs. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs were defined as events that started on or after the study medication start date and time.
| Percentage of participants | Canagliflozin + Metformin Hydrochloride FDC |
|---|---|
| Percentage of Participants With Adverse Drug Reactions (ADRs) | 10.6 |
Collected over Baseline (Day 1) up to end of study (28 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Canagliflozin + Metformin Hydrochloride FDC | 0/274 (0%) | 3/274 (1.1%) | 114/274 (41.6%) |
| Event | Canagliflozin + Metformin Hydrochloride FDC |
|---|---|
| Urinary Tract InfectionInfections and infestations | 2/274 |
| COVID-19Infections and infestations | 1/274 |
| Diabetic KetoacidosisMetabolism and nutrition disorders | 1/274 |
| ProstatomegalyReproductive system and breast disorders | 1/274 |
| Event | Canagliflozin + Metformin Hydrochloride FDC |
|---|---|
| PyrexiaGeneral disorders | 13/274 |
| DyslipidaemiaMetabolism and nutrition disorders | 13/274 |
| Genital InfectionInfections and infestations | 9/274 |
| HypoglycaemiaMetabolism and nutrition disorders | 9/274 |
| Urinary Tract InfectionInfections and infestations | 7/274 |
| AstheniaGeneral disorders | 5/274 |
| COVID-19Infections and infestations | 5/274 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/274 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 5/274 |
| ProteinuriaRenal and urinary disorders | 5/274 |
Safety analysis set included all participants who had taken at least 1 dose of study treatment.
| Age, Continuous(years) | Canagliflozin + Metformin Hydrochloride FDC |
|---|---|
| Mean | 52.1 ± 8.34 |
| Sex: Female, Male(Participants) | Canagliflozin + Metformin Hydrochloride FDC |
|---|---|
| Female | 106 |
| Male | 168 |
| Race/Ethnicity, Customized(Participants) | Canagliflozin + Metformin Hydrochloride FDC |
|---|---|
| Indian | 274 |
| Region of Enrollment(Participants) | Canagliflozin + Metformin Hydrochloride FDC |
|---|---|
| India | 274 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Nov 2020 to primary completion in Jul 2022, 20 months.
Results were first posted in Aug 2023, 1 year after primary completion.
Of 48 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 20 months is above that.
Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Canagliflozin · Metformin
Johnson & Johnson Private Limited →